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Abstract
Background: Occult HBV infection accelerates the progression of liver fibrosis, cirrhosis, and finally leading to
hepatocellular carcinoma (HCC). This study analyzed the occult HBV-genotypes in HCC patients.
Methods: To achieve our objective, matched serum and tissue samples were collected from 40 HCC patients.
Three sets of primers were used for the HBV-DNA detection by nested-PCR, which cover the HBV-genome; Core,
Surface and X genes. Genotyping system based on PCR using type-specific primers was applied on HBV-DNA
positive samples.
Results: Intrahepatic occult HBV-DNA was detected in 62.5%, whereas; Serum occult HBV-DNA were detected in
only 22.5% of HCC patients. In patients’ positive for both anti-HBs and anti-HBc, 10% had occult HBV in serum. In
serologically negative HCV patients, 63% had intrahepatic HBV-DNA, and 21% had HBV-DNA in serum samples.
HBV-genotype D (32%) and B (24%) attributed predominantly to intrahepatic HBV infections in HCC patients,
whereas HBV-genotype A (4%) and C (8%) infections were the least observed.
Conclusion: This is the first study to show the genotypes of occult HBV infection in HCC Patients. We suggest that
B or D may influence the outcome of HBV infection which may lead to the development of HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors worldwide [1] ranging
between 3% and 9% annually [2]. In Egypt, HCC reports
to account for about 4.7% of chronic liver disease
patients [3]. HBV and HCV infections are strongly asso-
ciated with liver cirrhosis and HCC [4]. Africa is one of
the highly endemic regions of HBV, with 5 genotypes
A-E are reported as predominant genotypes in different
countries [5,6]. HBV is a serious public health problem
worldwide and major cause of chronic hepatitis, cirrho-
sis, and HCC [7,8]. The diagnosis of HBV infection is
usually based on the detection of hepatitis B surface
antigen (HBsAg). Occult hepatitis B is defined by the
presence of HBV DNA in serum or liver in the absence
of HBsAg [9,10]. HBV DNA can be detected in patients
with chronic liver disease who are negative for HBsAg
but positive for antibodies to hepatitis B core antigen
(anti-HBc) [11,12]. The diagnosis depends on the
sensitivity of HBV DNA assays and the prevalence of
HBV infection in the population [11,13].
The occult HBV infection has frequently been identi-
fied in patients with chronic HCV infection, and in such
patients, this occult infection may be associated with
more severe liver damage and even the development of
HCC [14]. Occult HBV infection has found in indivi-
duals without HBV serological markers, past HBV infec-
tion, and with HCC patients with or without chronic
hepatitis C [15]. Occult HBV infection has been asso-
ciated with cryptogenic chronic hepatitis and HCC.
Furthermore, some studies suggested that occult hepati-
tis B might affect responsiveness of chronic hepatitis C
to interferon therapy and disease progress [14].
There is little information of HBV genotypes and its
relation to occult infection despite the importance of
this infection in Egypt. Taking into consideration the
impact of the fact that HBV and HCV infections are
common in Egyptian HCC patients, we investigate the
genotyping of occult HBV infection in Egyptian HCC
patients with or without HCV infection. * Correspondence: mohhafez_2000@yahoo.com
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This study included 40 histological confirmed HCC-
HBsAg-negative Patients; with mean age of 55 ± 4.9 years,
male to female ratio 4:1, who underwent surgical resection
in the National Cancer Institute-Cairo University. Ten
patients had HBsAg-positive samples and included as a
control group, tissue and blood samples were obtained
from all the patients. The study protocol was performed
according to the principles of Helsinki Declaration, and
informed consent was obtained from all the patients.
All serologic markers for HBV infection (HBsAg, anti-
HBs, anti-HBc, and anti-HBs) were detected with cur-
rent standard assays (Adalts, Italy) and antibodies to
HCV with HCV EIA version 3.0 according to the manu-
facturer’s instructions (Adalts, Italy).
Detection of occult HBV DNA
In this study, we investigated the presence of HBV DNA
by nested-PCR. We use three primer sets each specific for
Surface, Core, and X viral genomic regions, respectively, in
both tumor liver tissues and sera of patients as previously
described [16] (Table 1). DNA extracted from the serum
by QIAGEN viral DNA extract i o nk i t( Q I A G E N )u s i n g
140 μl of patient serum according to the manufacturer’s
procedure, and from frozen liver specimens by standard
Procedures [16]. In brief, 50 mg tissue specimens were
homogenized in buffer (150 mmol/L NaCl, 50 mmol/L
Tris-HCl (pH7.4), 10 mmol/L EDTA, 1% SDS), and incu-
bated overnight with proteinase K (800 μg/mL) at 37°C.
After extraction with phenol/chloroform the nucleic acids
were precipitated with ethanol. Nucleic acids were then
resuspended and digested with pancreatic ribonuclease
(100 μg/mL) followed by extraction with phenol/chloro-
form, and re-precipitation in pure cold ethanol. The DNA
was resuspended in 10 mmol/L Tris-HCl (pH 7.4),
1 mmol/L EDTA, and its concentration was determined
by using a UV spectrophotometer (Nanodrop). Amplifica-
tion of the b-actin gene was performed to test for the pre-
sence of artifacts as well as to set a baseline for tissue
sample that enables the evaluation of the target genes in
the HBV PCR. The amplified products were visualized on
an ethidium bromide-stained 2% agarose gel.
HBV-Genotype analysis
The determination of genotypes A through F of hepatitis
B virus was done according to previous described method
[17,18]. The sequences of PCR primers used in this study
are shown in table 2. In brief, the first and second- round
PCR primers were designed on the basis of the conserved
nature of nucleotide sequences in regions of the pre-S1
through S genes, irrespective of the six HBV genotypes
[17]. P1 and S1-2 were universal outer primers. B2 was
used as the inner primer with a combination called mix
A for genotypes A, B, and C. The first PCR was carried
out in 40 ul of a reaction mixture containing 100 ng of
each outer primer, a 200 mM concentration of each of
the four deoxynucleotides, 2.5 U of Taq DNA polymerase
(Promega, France) 1× PCR buffer containing containing
( 5 0m MK C l ,1 0m MT r i sp H8 . 3 )a n d1 . 5m MM g C l 2 .
The cycling protocol included one cycle of 5 min at 95°C,
followed by 40 cycles consisting of 94°C for 1 min, 55°C
for 1 min and 72°C for 2 min. Two second-round PCRs
were performed for each sample, with the common uni-
versal sense primer (B2) and mix A for types A through
C and the common universal antisense primer (B2R) and
mix B for types D through F.
A 1 ul aliquot of the first PCR product was added to
two tubes containing the second sets of each of the
inner primer pairs, each of the deoxynucleotides, Taq
DNA polymerase, and PCR buffer, as in the first reac-
tion. These were amplified for 40 cycles with the follow-
ing parameters: preheating at 95°C for 5 min, 30 cycles
of amplification at 94°C for 1 min, 58°C for 1 min, and
72°C for 1.30 min Genotypes of HBV for each sample
were determined by identifying the genotype-specific
DNA bands. The two different second-round PCR pro-
ducts from one sample were visualized on an ethidium
bromide- stained 3% agarose gel.
Detection of HCV RNA
Nucleic acid extraction was done by Mini-extraction kit
(QIAGEN) using 140 μl of patient serum according to
manufacturer’sp r o c e d u r e .R Ta n dP C Rw e r ed o n ea s
previously described [17] with primers from the most
conserved 5’ UTR of viral genome.
Statistical analysis
Data were analyzed by the chi-square test. A P value of
less than 0.05 considered statistically significant.
Table 1 Sequences of primer pairs
16 used for HBV PCR
detection
Core gene
C1s: 5’CTGGGAGGAGTTGGGGGA3’ 1730-1747
C2a: 5’GTAGAAGAATAAAGCCC3’ 2503-2487
C3s: 5’GGTCTTTGTACTCGGAGGCTG3’ 1763-1783
C4a: 5’ATACTAACATTGACATTCCC3’ 2455-2436
Surface gene
S-1s: 5’AGAACATCGCATCAGGACTC3’ 159-178
S-2a: 5’CATAGGTATCTTGCGAAAGC3’ 642-623
S-3s: 5’AGGACCCCTGCTCGTGTTAC3’ 181-200
S-4a: 5’AGATGATGGGATGGGAATAC3’ 619-600
X gene
X1s: 5’CTAGCCGCTTGTTTTGCTCG3’ 1282-1301
X2a: 5’TTATGCCTACAGCCTCCTAG3’ 1666-1647
X3s: 5’GGTCTTACATAAGAGGACTC3’ 1518-1537
X4a: 5’GTTCACGGTGGTCTCCAT3’ 1625-160
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Characteristics of the participants were shown in table 3.
Out of these forty patients, 19 had serological positive
HCV infection with elevated ALT. Tissue and serum
samples were considered HBV DNA reactive if at least
two of the three PCR assays positive. The intrahepatic
HBV genes were the Surface 18/40 (45%), X 16/40
(40%) and Core genes 26/40 (65%) in the occult patients
compared to 10/10(100%), 6/10(60%) and 6/10(60%) in
control group respectively. There was no difference
observed in prevalence of intrahepatic occult HBV infec-
tion in relation to age or sex.
In the HBsAg negative HCC patients, out of 25 intra-
hepatic HBV-DNA, 40% hadH C V - R N A ,7 2 %h a dl i v e r
cirrhosis. According to tumor grade 16%, 52% and 32%
had tumor grade I, II, and III respectively. Intrahepatic
HBV DNA was detected in (25/40) 63%, of them seven
(28%) had both X and Core genes, five (20%) had both S
and X genes, and 11(44%) had S and C genes. Only two
cases out of 25 (8%) had all genes. In the control group,
HBV-DNA was detected in all liver tissues, all had
S-gene, of them six had both X and Core genes. Out of
the twenty-five cases eleven (44%) had both anti-HBc-
IgG and anti-HBs. HCV RNA was found in the serum
of 10/25 (40%). Nine of ten (90%) HCV-RNA positive
patients had detectable serum HBV-DNA. Seventy-two
percentage of these cases (18/25) had liver cirrhosis.
HBV DNA-positive patients had significantly high
tumor grade I and II compared to HBV-DNA negative
patients.
In serum, HBV-DNA was detected in 20 of 40 patients
(50%), 16/40 (40%), 13/40 (32.5%), 4/40 (10%) had X, S
and Core gene respectively. HBV DNA were detected in
only 9/40 (22.5%) of HCC patients. Among the 40 HCC
patients with different serological patterns for HBV
infection, occult HBV infection was 4/40 (10%) in cases
positive for both anti-HBs and anti-HBc. The overall
prevalence was significantly higher for those positive for
anti-HBc alone or with anti-HBs than for those negative
for all markers (p = 0.001).
This study showed, as in table 4, that intrahepatic
HBV infections are attributed predominantly to viral
genotypes D and B that constituted 8/25 (32%) and 6/25
(24%), respectively. HBV genotypes A and C infections
were the least observed and constituted 4% and 8%
respectively compared 100% of HBV genotype A and D
mixed infections in the control group with no other
genotype observed. In addition, there was a relatively
high prevalence of mixed infections of 5/25(20%) among
the studied group. One case had both genotypes A and
D, 2 cases had both B and D and 2 cases had genotypes
B and C. No HBV genotype E or F was found in our
study and furthermore, genotypes G and H were not
determined.
In the serological HCV-related HCC, the serum occult
HBV infection was 47.4% (9/19). The prevalence of
occult HBV infection was higher in patients having both
anti-HBs and anti-HBc 2/4 (50%) than those having
anti-HBc alone 1/5 (20%). In our previous study among
Table 2 HBV genotyping primers sequence
Primer Sequence a(position, specificity, and polarity)
First PCR
P1 5’-TCA CCA TAT TCT TGG GAA CAA GA-3’ (nt 2823-2845, universal, sense)
S1-2 5’-CGA ACC ACT GAA CAA ATG GC-3’ (nt 685-704, universal, antisense)
Second PCR
Mix A
B2 5’-GGC TCM AGT TCM GGA ACA GT-3’ (nt 67-86, types A to E specific, sense)
BA1R 5’-CTC GCG GAG ATT GAC GAG ATG T-3’ (nt 113-134, type A specific, antisense)
B1R 5’-CAG GTT GGT GAG TGA CTG GAG A-3’ (nt 324-345, type B specific, antisense)
BC1R 5’-GGT CCT AGG AAT CCT GAT GTT G-3’ (nt 165-186, type C specific, antisense)
Mix B
BD1 5’-GCC AAC AAG GTA GGA GCT-3’ (nt 2979-2996, type D specific, sense)
BE1 5’-CAC CAG AAA TCC AGA TTG GGA CCA-3’ (nt 2955-2978, type E specific, sense)
BF1 5’-GYT ACG GTC CAG GGT TAC CA-3’ (nt 3032-3051, type F specific, sense)
B2R 5’-GGA GGC GGA TYT GCT GGC AA-3’ (nt 3078-3097, types D to F specific, antisense)
a An “M” represents a nucleotide that could be either an A or a C; a"Y” represents a nucleotide that could be either a C or a T. nt: nucleotide.
Table 3 The characteristics of the study subjects
Characteristics
No. of the participants 40
No. of the controls 10
Age-years (range)* 55 ± 9 (25-72)
Sex Male/Female 32/8
Elevated serum ALT levels with HCV Ab 19/40 (45%)
Anti-HBs 16/40(40%)
Anti-HBc 30/40(75%)
*Expressed as mean+SD (range); ALT (normal range (0-41 IU/L).
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otypes 4a was the most common [19], and according to
the presence or absence of occult HBV infection, there
was no significant difference in the mean serum ALT
level.
Discussion
Occult HBV infection is characterized by positivity for
HBV DNA in HBsAg-negative patients with or without
serological markers of previous HBV infection [20].
Occult HBV infection has been commonly reported
among immunocompromised patients [21-23]. In Egypt,
occult HBV infection is 9/712 (1.26%) in the blood
donors accepted blood donations [24]. In this study, the
prevalence of the intrahepatic HBV-DNA was 63%.
Similarly, in another studies on the HCC patients, it var-
ies from 22%- 87% [12,25] and among general popula-
tion in different countries to be ranged from 2-16%
[15,26]. Occult HBV prevalence was significantly high
among HCC, chronic hepatitis C, or under hemodialysis
[10,27,28]. HBV may be also reactivated in patients
undergoing anti-cancer chemotherapy [12,29]. Occult
HBV infection may occur after complete clinical recov-
ery from acute self-limited hepatitis so; HBsAg sero-
clearance does not necessarily imply HBV eradication
[30,31]. In endemic areas, the anti-HBc IgG and anti-
H B sa sw e l la sH B s A gw e r en o ts u f f i c i e n tm a r k e r st o
exclude HBV-DNA carriers [32].
The presence of occult HBV during chronic HCV
infection is well described, the observed high proportion
of HCV-related HCC cases show occult HBV infection,
was similarly in the previous epidemiological surveys
that found close relationship between the existence of
HCV and the occurrence of HCC in HBsAg-negative
HCC [20,33,34]. Our study showed the serum occult
HBV infection to be 47.4% (9/19) in HCV- HCC
patients. The prevalence of occult HBV infection was
particularly high among patients with HBV antibodies.
In our study, the intrahepatic HBV DNA was detected
in 42.1% (8/19) of the HCV-Ab positive patients. Only
14.2% (3/21) patients without HCV-Ab have HBV-DNA
in the liver tissue. Similarly, its prevalence in HCV
patients is reported to be 40-50% in liver tissue [7,9].
There was an elevated risk in HCV patients because this
silent infection can affect the progression and HCC
development [19].
The prevalence of occult HBV infection was higher in
subjects having either anti-HBs or anti-HBc or both
anti- HBs and anti-HBc. Our results revealed that in 19
patients with HCV infection, it was higher in patients
having both anti-HBs and anti-HBc 50% than those hav-
ing anti-HBc alone 20%. In an Egyptian chronic HCV
patients study, they found that those positive for anti-
HBc had severe liver disease compared to negative ones.
Serum HBV-DNA was 22.5% in anti-HBc-positive
chronic HCV patients and nothing detected in anti-
HBc-negative chronic HCV patients [35]. Similarly, sero-
logical findings in patients with occult hepatitis B and
HCV co-infection revealed that 35% of people were
HBsAb positive, 42% were anti-HBc IgG positive, and
22% were negative for both [28]. In Northern countries,
no more than 5% of HBsAg-/anti-HBc+ blood donor
samples contain HBV DNA [36]. In West Africa, 5% of
total HBV DNA carriers are HBsAg negative [37].
HCC patients living in endemic areas for HBV were
frequently found positive for HBsAg and/or anti-HBc
antibodies and this strong relationship was the first epi-
demiological evidence of HBV-related oncogenic trans-
formation [38]. Among our 40 HCC patients with
different serological patterns for HBV infection, the
prevalence of occult HBV infection was 10% in both
anti-HBs and anti-HBc positive cases, and 0% in cases
negative for all markers. The overall prevalence was sig-
nificantly higher for those positive for anti-HBc alone or
with anti-HBs than for those negative for all markers.
Data presented here sowed that out of the intrahepatic
HBV DNA positive cases, 56% were only anti-HBc-IgG
positive, while 44% were both anti-HBc-IgG and anti-
HBs positive. A higher frequency of HBV-DNA, among
anti-HBc positive patients 46% than in anti-HBc nega-
tive patients (20%) has previously reported [39]. We sug-
gested that while HBV is not the only factor in HCC
development in Egypt, it is still one of the major risks.
Occult HBV has associated with more advanced fibro-
sis/cirrhosis [40]. Our study shows that 72% of the HCC
patients with intrahepatic occult HBV had cirrhosis. Cir-
rhosis is considered as an important risk factor for the
development of HCC [41-44]. In addition, occult
HBV infection may favor neoplastic transformation in
Table 4 Correlation between clinical and virological data
in the intrahepatic HBV DNA
Variables No.(%)
HCV-RNA 10/25 (40%)
High AFP 15/25(60%)
Liver cirrhosis 18/25(72%)
Tumor Grade I 4/25(16%)
Tumor Grade II 13/25(52%)
Tumor Grade III 8/25(32%)
X-gene and HBcIgG +ve 12/25(48%)
S-gene and HBcIgG +ve 16/25(64%)
C-gene and HBcIgG +ve 20/25(80%)
HBV genotype A 1/25 (4%)
HBV genotype B 6/25 (24%)
HBV genotype C 2/25 (8%)
HBV genotype D 8/25 (32%)
HBV mixed genotype 5/25 (20%)
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rhosis. Many epidemiologic and molecular studies indi-
cate that persistent HBV infection may have a critical
role in the development of HCC in HBsAg-negative
patients [45].
Using PCR primers located in several HBV genes, HBV
DNA can be amplified in many tissues but not all cases
[46]. In this study, intra-hepatic HBV genes were exam-
ined in the forty HCC participants in whom the Surface,
X and Core genes were detected in 45%, 40%, and 65%,
respectively. In intra-hepatic HBV DNA positive cases,
28% were positive for X and Core genes, 20% were posi-
tive for Surface and X genes, and 44% were positive for
Surface and Core genes. Only 8% were positive for Sur-
face, X and Core genes. The prevalence of occult HBV
infection did not differ with age or sex. The persistent
HBV infection may have a critical role in the develop-
ment of HCC in HBsAg-negative patients. One of the
markers in HCC cases, HBsAg (-), has been the presence
of the HBV-X gene expression in HCC since positivity
for the HBV-X protein in liver tissue in several studies
reached half of the liver tissues specimens. In several
reports the PCR for S gene was sensitive in serum
whereas the X gene was sensitive in the liver [28]. The X
gene deregulates cell cycle control, interferes with cellu-
lar DNA repair and apoptosis, and plays an important
role in interaction with p53 and Rb gene [47].
HBV genotype was a factor that influencing the fre-
quency of occults HBV. In this study the intrahepatic
HBV infections in HCC cancer patients are predomi-
nantly to viral genotypes D and B that constituted 8/25
(32%) and 6/25 (24%), respectively. HBV genotypes A
and C infections were the least observed and constituted
4% and 8% respectively. In addition, there was a rela-
tively high prevalence of mixed infections of 5/25(20%)
among the studied group. One case had both genotypes
A and D, 2 cases had B and D and 2 cases had geno-
types B and C. Similarly, in our previous study, we
found that HBV mixed genotype infections could prob-
ably be of clinical significance in HBV-induced liver dis-
eases, in which a prevalence of mixed genotype
infections in the study participants was 15.7% especially
those with CAH. HBV genotype A and D mixed infec-
tions accounted for 45.5% of the total mixed infections.
Occult HBV during the non-replicative phase is there-
fore expected to be more frequent in areas where geno-
types A, D, and E are prevalent [18].
In conclusion, occult HBV infection and the HBV
genotype B or D may influence the outcome of HBV
infection leading to the development of hepatocellular
carcinoma and may have a strong association with HCV
in the carcinogenesis of liver. A decrease in the immune
status may result in HBV reactivation in anti-HBs posi-
tive patients undergoing chemotherapy.
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